| Filed On | Filing |
|---|---|
| 31 Jul 2026 | DATROWAY APPROVED IN EU FOR TNBC |
| 27 Jul 2026 | UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA |
| 27 Jul 2026 | FORM 6-K |
| 27 Jul 2026 | SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS |
| 23 Jul 2026 | ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER |
| 14 Jul 2026 | ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR |
| 09 Jul 2026 | UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL |
| 08 Jul 2026 | OWNERSHIP DOCUMENT |
| 01 Jul 2026 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 01 Jul 2026 | TOTAL VOTING RIGHTS |
| 29 Jun 2026 | FORM 11-K |
| 29 Jun 2026 | ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS |
| 29 Jun 2026 | DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC |
| 16 Jun 2026 | OWNERSHIP DOCUMENT |
| 15 Jun 2026 | TRUQAP APPROVED IN US FOR PROSTATE CANCER |
| 01 Jun 2026 | TOTAL VOTING RIGHTS |
| 01 Jun 2026 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 29 May 2026 | IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER |
| 28 May 2026 | 25-NSE |
| 27 May 2026 | US FDA DECISION DATE ON CAMIZESTRANT EXTENDED |
Loading...
